Phase 2 N=10 Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
Discoid Lupus Erythematosus
Primary: Mean Severity of Disease as Measured by the Investigator's Global Assessment — 1.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Lupus Erythematosus, Discoid · Lupus Erythematosus, Systemic
Primary: Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions. — 22.2; 27.8 percentage of subjects
N/A N=31 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants
N/A N=6 Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale
N/A N=5 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus (CLE)
Primary: Cutaneous Lupus Area and Severity Index (CLASI) — 21.4; 10.8; 8.6; 5.3 units on a scale
Phase 1 N=7 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Cutaneous Lupus
Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells
Phase 1 N=11 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
Lupus Erythematosus, Cutaneous
Primary: Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria — 0; 11; 0; 10 Participants
Phase 2 N=25 A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus — 11; 4 Participants
Phase 2 N=78 Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12 — -37.05; -42.76 percent change
Phase 2 N=264 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · Active Cutaneous Lupus Erythematosus
Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037
Phase 2 N=12 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
Discoid Lupus Erythematosus
Primary: Cutaneous LE Diseases Area and Severity Index (CLASI) Score Based on Extent of Symptoms
Phase 2 N=64 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo. — -6.2; -6.5; -6.2; -5.7 Scores on a scale — p=0.845
N/A N=699 Women Empowered to Live With Lupus Study
Lupus Erythematosus, Systemic
Primary: Communication With Physician - Stanford 3Q Scale Score — 3.1; 2.9; 3.3; 3.0 score on a scale
Phase 2 N=182 A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response…
Phase 2 N=12 Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 2 N=187 Study of Anti-Malarials in Incomplete Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: SLICC Score — 62; 56; 46; 41 participants — p=0.72
Phase 2 N=102 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…
Phase 2 N=24 Dexamethasone Solution for the Treatment of Oral Lichen Planus
Lichen Planus
Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale
Phase 2 N=57 Vitamin D3 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Percent of Participants With an IFN Alpha Signature Response at Week 12 — 36.8; 23.5; 27.8; 25.7 Percent of participants — p=0.53
Early Phase 1 N=16 IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS) — 100; 94; 84; 94 Percent of Baseline
Phase 2 N=456 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Systemic Lupus Erythematosus
Primary: Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16 — -5.0; -9.0; -10.2; -9.7 scores on a…
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=47 Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 — -4.5; -8.7; -5.5 score on a scale — p=0.7500
Phase 2 N=8 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Dermatomyositis, Adult Type
Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…
Phase 2 N=9 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Relapse-free Complete Clinical Response — 54 Months
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares